Net profit of Jenburkt Pharmaceuticals rose 31.15% to Rs 9.60 crore in the quarter ended September 2024 as against Rs 7.32 crore during the previous quarter ended September 2023. Sales rose 7.65% to Rs 41.22 crore in the quarter ended September 2024 as against Rs 38.29 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales41.2238.29 8 OPM %27.7323.77 - PBDT13.1610.13 30 PBT12.529.54 31 NP9.607.32 31 Powered by Capital Market - Live News

Jenburkt Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 5 November 2024Powered by Capital Market - Live News

Net profit of Jenburkt Pharmaceuticals rose 38.18% to Rs 7.42 crore in the quarter ended June 2024 as against Rs 5.37 crore during the previous quarter ended June 2023. Sales rose 11.51% to Rs 32.54 crore in the quarter ended June 2024 as against Rs 29.18 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales32.5429.18 12 OPM %28.5523.85 - PBDT10.597.93 34 PBT10.077.43 36 NP7.425.37 38 Powered by Capital Market - Live News

Jenburkt Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 26 July 2024.Powered by Capital Market - Live News

Jenburkt Pharmaceuticals announced that the 39th Annual General Meeting (AGM) of the company will be held on 30 July 2024.Powered by Capital Market - Live News